Hyperdynamics Corporation (NYSE:HDY) shares up by 2.30%, DARA Biosciences Inc (NASDAQ:DARA)

Posted by Nathan Alexander May 29, 2013 0 Comment 1059 views


Hartford, CT 05/29/2013 (GDPInsider) – Hyperdynamics Corporation (NYSE:HDY) shares closed at $0.520 up by 2.30% (+$0.012) compared to previous day’s close of about $0.51. It touched a high of $0.53 and low of $0.50 during the day. It is about 61.74% below its 52 week high of $1.32 and about 7.45% above its 52-week low of $0.47. Around 0.256 million Shares have exchanged hands during last trading session which is lower as compared to average shares changed during a period of 30 days which is 0.395 million. The market capitalization of the company is $84.29 million. The earnings per share of the company are -$0.92 which shows that the company is incurring losses. The average true range of the stock is 0.03. The high current ratio of the company 2.07 shows good capital working capital management. The beta of the company is 2.12. Hyperdynamics Corporation is the company based on oils and gases.

Is HDY a solid investment at these levels? Get valuable updates and exclusive insights here.

DARA Biosciences Inc (NASDAQ:DARA) shares closed at $0.721 dropped by 1.23% (-$0.009) compared to previous day’s close of about $0.73. It touched a high of $0.75 and low of $0.71 during the day. It is about 47.83% below its 52 week high of $1.38 and about 16.13% above its 52-week low of $0.62. Around 0.264 million Shares have exchanged hands during last trading session which is lower as compared to average shares changed during a period of 30 days which is 0.297 million. The market capitalization of the company is $13.46 million. The earnings per share of the company are -$1.03 which shows that the company is incurring losses. The average true range of the stock is 0.04. The high current ratio of the company 6.54 shows good capital working capital management. The beta of the company is 1.35.

The exclusive marketing rights of United States are held by the company to its oral liquid tamoxifen named Soltamox.

How Should Investors Trade DARA Now? Get key and important information right here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Nathan Alexander

Nathan Alexander holds bachelor’s degrees in Journalism and European Studies from Boston University. Nathan reports round up the day’s business and financial market news and include keynote interviews with major business players and updates on Asian, European and US stock markets. He has interviewed heads of leading European banking institutions such as European Central Bank President Jean-Claude Trichet and HSBC Chairman Stephen Green, and CEOs from the business world including Microsoft founder Bill Gates, Virgin Chairman Sir Richard Branson and former Porsche President and CEO Dr Wendelin Wiedeking.

View all post by Nathan Alexander Visit author's website

Write Your Comment